The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
Abstract
Background: Secukinumab is a fully human anti–interleukin‐17A monoclonal antibody. Objective: Determine the efficacy, safety and usability of secukinumab administered via autoinjector/pen. Methods: This phase III trial randomized subjects with moderate to severe plaque psoriasis to secukinumab 300 mg, 150 mg or placebo self‐injection once weekly to Week 4, then every 4 weeks. Co‐primary end points at Week 12 were ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) and clear/almost clear skin by investigator's global assessment 2011 modified version (IGA mod 2011 0/1). Secondary end points included autoinjector usability, assessed by successful, hazard‐free self‐injection and subject‐reported acceptability on Self‐Injection Assessment Questionnaire. Results: Week 12 PASI 75 and IGA mod 2011 0/1 responses were superior with secukinumab 300 mg (86.7% and 73.3%, respectively) and 150 mg (71.7% and 53.3%, respectively) vs. placebo (3.3% and 0%, respectively) (P < 0.0001 for all). All subjects successfully self‐administered treatment at Week 1, without critical use‐related hazards. Subject acceptability of autoinjector was high throughout 12 weeks. Adverse events were higher with secukinumab (300 mg, 70.0%; 150 mg, 63.9%) vs. placebo (54.1%), with differences largely driven by mild/moderate nasopharyngitis. Conclusion: Secukinumab delivered by autoinjector/pen is efficacious, well‐tolerated and associated with high usability in moderate to severe plaque psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Self-citationThe Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
Immunopathogenic mechanisms in psoriasis
GUDJONSSON, J. E., JOHNSTON, A., SIGMUNDSDOTTIR, H., & VALDIMARSSON, H. (2003) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02310.x · Cited by 397
Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., Haemmerle, S., Thurston, H. J., Papavassilis, C., & Richards, H. B. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12110 · Cited by 360
Self-citationLangley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Self-citationRich, P., Sigurgeirsson, B., Thaçi, D., Ortonne, J. ‐., Paul, C. F., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12112 · Cited by 244
Self-citationZhang, L., Yang, X.-Q., Cheng, J., Hui, R.-S., & Gao, T.-W. (2010) · Clinical Immunology · doi:10.1016/j.clim.2009.11.008 · Cited by 211
Adherence in the Treatment of Psoriasis: A Systematic Review
Augustin, M., Holland, B., Dartsch, D. C., Langenbruch, A. K., & Radtke, M. A. (2011) · Dermatology · doi:10.1159/000329026 · Cited by 156
Cited by
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Self-citationSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Self-citationvan de Kerkhof, P. C. M., Griffiths, C. E. M., Reich, K., Leonardi, C. L., Blauvelt, A., Tsai, T.-F., Gong, Y., Huang, J., Papavassilis, C., & Fox, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.024 · Cited by 302
Self-citationComparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1882-2 · Cited by 292
Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Metadata
- Authors
- Paul, C., Lacour, J. ‐., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., Guindon, C., You, R., Papavassilis, C., & the JUNCTURE study group
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2014-09-22
- Volume
- 29
- Issue
- 6
- Pages
- 1082-1090
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W2103750969
- Cited by
- 280
- References
- 21
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.